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Abstract  
Introduction and Aims: The CYP2C19 
enzyme is involved in the metabolism of various 
therapeutically-important drugs including 
clopidogrel.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The aims were to determine CYP2C19 *2 and 
*17 variant allele frequencies and CYP2C19 
genotype distribution in a cohort of Maltese patients 
on clopidogrel and to compare observed frequencies 
of the CYP2C19 *2 allele and *2/*2 genotype in 
this cohort to other populations bordering the 
Mediterranean Sea. 
Methods: CYP2C19 genotyping in a cohort of 
Maltese patients on clopidogrel was performed 
using TaqMan™ Drug Metabolism Genotyping 
Assays. Frequencies of the CYP2C19 *2 and *17 
variant alleles and six genotypes (*1/*1, *1/*2, 
*2/*2, *1/*17, *17/*17, *2/*17) were determined. 
Observed frequencies of the *2 allele and *2/*2 
genotype were compared to fourteen populations 
bordering the Mediterranean Sea. 
Results: Frequency of the CYP2C19 *2 and 
*17 allele in the 244 Maltese patients genotyped 
was 12.3% and 15.4% respectively. CYP2C19 
genotype distribution was: *1/*1 (52.1%), *1/*17 
(22.5%), *1/*2 (18.0%), 2/*17 (6.6%), *17/*17 
(0.8%) and *2/*2 (0). There was no statistically 
significant difference in *2 allele frequency 
between the Maltese cohort and all fourteen 
populations bordering the Mediterranean Sea.  
Conclusions: This study reports the frequency 
of CYP2C19 *2 and *17 variant alleles in a cohort 
of Maltese patients treated with clopidogrel. The 
high percentage of patients genotyped as carriers of 
the *2 (25%) or *17 (23%) variant alleles indicates 
that CYP2C19 genotyping could be used to guide 
clinicians in the individualisation of antiplatelet 
therapy.  
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Introduction 
The CYP2C19 enzyme is involved in the 
metabolism of a number of therapeutically-important 
drugs, including the thienopyridine inactive prodrug 
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clopidogrel. Biotransformation in the liver is 
required to form the pharmacologically active 
metabolite of clopidogrel, which selectively and 
irreversibly antagonises the P2Y12 component of the 
adenosine diphosphate receptor on the platelet 
surface, consequently attenuating platelet 
aggregation.1 Two sequential hepatic oxidative steps 
are involved in clopidogrel bioactivation1 and 
CYP2C19 is the principal enzyme involved in both 
steps.2 CYP2C19 single nucleotide polymorphisms 
have been identified as significantly and consistently 
being associated with variability in clopidogrel 
response.3-5 Identifying patients’ genotype and ability 
to effectively transform clopidogrel to the active 
metabolite is crucial for individualisation of 
treatment in cardiology. 
The cytochrome P (CYP) 450 isoenzyme 
2C19 (CYP2C19) is highly polymorphic and more 
than 30 variant alleles have been identified.6 The 
CYP2C19 ‘*1’ ‘wild-type’ allele is associated with 
normal ‘functional’ CYP2C19-mediated 
metabolism and is assigned when variant alleles are 
not identified. The ‘*2’ variant allele is the most 
prevalent loss-of-function allele which translates 
into decreased drug metabolism and the ‘*17’ allele 
is a gain-of-function allele which may result in 
increased activity due to enhanced expression.3  
Frequencies of the CYP2C19 *2 and *17 
alleles in forty-one healthy Maltese volunteers have 
been reported.7 The aims of this study were to 
determine the frequency of the CYP2C19 *2 and 
*17 alleles and CYP2C19 genotype distribution in a 
cohort of Maltese patients on clopidogrel and to 
compare the frequencies of the *2 allele and *2/*2 
genotype observed in this cohort to other 
populations bordering the Mediterranean Sea. 
 
Methodology 
Ethics approval 
The study protocol was approved by the 
University of Malta Research Ethics Committee.  
 
Study design and setting 
This cohort study was undertaken at Mater 
Dei Hospital. Patients were prospectively identified 
from the cardiac catheterisation suite at the 
Department of Cardiology and CYP2C19 
genotyping was performed at the Molecular 
Diagnostics Unit of the Department of Pathology.  
 
 
 
Patient recruitment and sample collection 
Maltese patients ≥ 18 years undergoing 
percutaneous coronary intervention (PCI) with stent 
placement and prescribed dual antiplatelet therapy 
with aspirin and clopidogrel were recruited by non-
probability sampling over a twelve-month period 
(January-December 2014). The advantages of this 
sampling method are that it is cost and time-
effective. Although non-probability sampling does 
not guarantee that each patient has equal probability 
of being selected, the sample is a good 
representation of the population since the patients 
were recruited over a one-year period. After 
obtaining written informed consent, 5 mL of 
peripheral blood was collected from each patient in 
a purple-top ethylenediaminetetraacetic (EDTA) 
vacutainer at the time of PCI.  
 
Genomic DNA extraction and CYP2C19 
genotyping  
Genomic DNA was extracted from 200 µL of 
the EDTA-blood sample using the QIAamp® DNA 
Mini Kit on the fully automated QIAcube (Qiagen). 
CYP2C19 genotyping for the *2 (rs4244285) and 
*17 (rs12248560) alleles was performed with 
TaqMan™ Drug Metabolism Genotyping Assays 
(Thermo Fisher Scientific), which involve DNA 
amplification and homogeneous solution 
hybridisation using fluorescence resonance energy 
transfer, on the 7500 ABI real-time polymerase 
chain reaction (PCR) system (Applied Biosystems). 
Each well in the PCR plate had a final reaction 
volume of 25 µl consisting of gDNA, an allele-
specific probe labelled with VIC® dye and another 
with 6FAM™ dye, forward and reverse primers and 
TaqMan™ Universal PCR Master Mix (Thermo 
Fisher Scientific). Thermal cycling conditions 
consisted of initial denaturation at 95 °C for 10 
minutes, followed by 50 denaturation cycles at 92 
°C for 15 seconds and annealing/extension at 60 °C 
for 90 seconds. Patients were genotyped as 
homozygous (*1/*1, *2/*2, *17/*17) or 
heterozygous (*1/*17, *1/*2, *2/*17) for the 
CYP2C19 alleles. 
 
Categorisation of patients into metaboliser 
phenotypes for clopidogrel 
The observed genotypes were classified into 
four clopidogrel metaboliser phenotypes according 
to the Clinical Pharmacogenetics Implementation 
Consortium (CPIC) guidelines for CYP2C19 
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genotype and clopidogrel therapy4, namely 
extensive metabolisers - EMs (*1/*1), ultra-rapid 
metabolisers - UMs (*1/*17, *17/*17), intermediate 
metabolisers - IMs (*1/*2, *2/*17) or poor 
metabolisers - PMs (*2/*2). The caring 
cardiologists were informed of the genotype and 
phenotype results. 
 
Comparison of CYP2C19 polymorphisms in 
populations bordering the Mediterranean Sea 
The observed frequencies of the CYP2C19 *2 
allele and *2/*2 genotype in the Maltese patient 
cohort on clopidogrel were compared to fourteen 
populations bordering the Mediterranean Sea, 
namely Albanian, Bosnian, Croatian, Egyptian, 
Greek, Israeli, Lebanese, Moroccan, Slovenian, 
Southern French, Southern Italian, Southern 
Spanish, Tunisian and Turkish populations.  
 
Statistical analysis  
IBM SPSS Statistics 24 was used for 
statistical analysis. Observed and expected 
CYP2C19 genotype frequencies were compared 
using the Hardy-Weinberg (H-W) equilibrium 
calculation. The Fisher’s exact test was used to 
determine whether the observed data supports the 
null hypothesis that the cohort is in H-W 
equilibrium by adopting a 0.05 level of 
significance. Observed proportions of the CYP2C19 
*2 allele and *2/*2 genotype in the study cohort 
were compared to the fourteen populations 
bordering the Mediterranean Sea using the 
difference of two proportions z-test. A p-value less 
than 0.05 indicates that the proportions differ 
significantly, while a p-value greater than 0.05 
indicates a non-significant (NS) difference, hence 
comparable proportions. 
 
Results 
Two hundred and forty-four (29%) Maltese 
patients on clopidogrel (75% male, mean age 65.43 
±1.24 years, all Caucasian, 45% undergoing PCI 
following admission with acute coronary syndrome) 
out of the total 843 Maltese and non-Maltese 
patients who underwent PCI from January to 
December 2014 were genotyped for the CYP2C19 
*2 and *17 alleles.  
CYP2C19 *1, *2 and *17 allele frequencies 
were 72.3%, 12.3% and 15.4% respectively. 
CYP2C19 genotype distribution of the 244 patients 
was *1/*1 (52.1%), *1/*17 (22.5%), *1/*2 (18.0%), 
*2/*17 (6.6%) and *17/*17 (0.8%). No patients 
were genotyped as *2/*2. Since there was a 
discrepancy between the observed frequencies and 
the corresponding expected frequencies, particularly 
for the *2/*17, *2/*2 and *17/*17 genotypes, the 
Fisher’s exact p-value obtained (0.051) is very close 
to the 0.05 threshold for H-W equilibrium (Table 
1).  
 
 
 
Table 1: Observed and expected CYP2C19 genotypes (N=244) 
 
CYP2C19 
genotype 
Observed number (%) 
Expected number (%) 
H-W 
Χ2; p-value  
(Fisher’s exact test) 
H-W 
*1/*1 127 (52.1) 127.5 (52.3) 
X2(5) = 11.04; 
p=0.051 
*1/*17 55 (22.5) 54.3 (22.3) 
*17/*17 2 (0.8) 5.8 (2.4) 
*1/*2 44 (18.0) 43.4 (17.8) 
*2/*17 16 (6.6) 9.3 (3.8) 
*2/*2 0 (0) 3.7 (1.5) 
H-W: Hardy-Weinberg 
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Table 2: Distribution of CYP2C19 *2 allele and *2/*2 genotype: Maltese cohort compared to other 
populations bordering the Mediterranean Sea 
 
 
Population 
 
Number of patients  
(number of alleles) 
Frequency %  
(p-value) 
Frequency %  
(p-value) 
CYP2C19 *2 CYP2C19 *2/*2 
Maltese  
Present study 
244  
(488) 
12.3 0 
Albanian8 
40 
(80) 
20.0 
(NS) 
2.5 
(S) 
Bosnian9 
 
77 
(154) 
16.9  
(NS) 
2.6  
(S) 
Croatian10 
 
200  
(400) 
15.0 
(NS) 
3.0  
(S) 
Egyptian11  
 
247  
(494) 
10.9 
(NS) 
0.8  
(NS) 
Greek12  
 
283  
(566) 
13.1 
(NS) 
2.1  
(S) 
Israeli13 
 
140  
(280) 
15.0 
(NS) 
2.9  
(S) 
Lebanese14 
 
161  
(322) 
13.4 
(NS) 
3.1  
(S) 
Moroccan15 
 
290  
(580) 
11.4 
(NS) 
0.3 
(NS) 
Slovenian16  
129  
(258) 
15.9 
(NS) 
0.8  
(NS) 
Southern French17  
(Marseille, Nimes)  
213  
(426) 
12.0 
(NS) 
1.0  
(NS) 
Southern Italian18 
(Messina)  
360  
(720) 
11.1 
(NS) 
1.7  
(S) 
Southern Spanish19 
(Valencia) 
362  
(724) 
13.1 
(NS) 
1.9  
(S) 
Tunisian20  
100  
(200) 
11.5 
(NS) 
0  
(NS) 
Turkish21 
404  
(808) 
12.0 
(NS) 
1.0  
(NS) 
S – significant; NS - not significant 
 
 
When classifying the patients according to 
metaboliser phenotype relative to clopidogrel, 
52.1% of the patients were EMs, 24.6% were IMs, 
23.4% were UMs and no patients were PMs.  
Frequencies of the *2 allele ranged from 
10.9% in Egyptians to 20% in Albanians (Maltese 
patients 12.3%). Prevalence of the *2 allele in the 
Maltese cohort is comparable (NS) to all fourteen 
populations bordering the Mediterranean Sea. 
Frequencies of the *2/*2 genotype ranged from 0% 
in Tunisians to 3.1% in Lebanese (Maltese patients 
0%). Prevalence of the *2/*2 genotype in the 
Maltese patient cohort is comparable (NS) to six 
populations bordering the Mediterranean Sea, 
namely Egyptian, Moroccan, Southern French, 
Slovenian, Turkish and Tunisian populations (Table 
2). 
 
Discussion  
This is the first report on the frequency of 
CYP2C19 *2 and *17 genetic polymorphisms in 
Maltese patients on clopidogrel therapy.  
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The frequency of the CYP2C19 *2 allele in 
this cohort of Maltese patients taking clopidogrel 
(12.3%) is lower than the reported prevalence in 
healthy Maltese volunteers (20%)7 and in 
Europeans and Africans (18%).22 The *2 allele 
frequency in the patient cohort studied is 
comparable to the fourteen populations bordering 
the Mediterranean Sea included in the comparison 
since no statistically significant difference was 
observed.  
The reported prevalence of the CYP2C19 *17 
allele in healthy Maltese volunteers (26%)7 and in 
Europeans and Africans (22.4% and 23.5% 
respectively)22 is higher than the frequency 
observed in this Maltese patient cohort (15.4%). 
The prevalence of the CYP2C19 *17 allele was 
studied in three populations bordering the 
Mediterranean Sea, namely Southern French17, 
Southern Spanish19 and Greek23, with a higher 
observed frequency (20%) compared to the Maltese 
cohort (15.4%). However, the difference was not 
statistically significant for all three populations.  
Prevalence of CYP2C19 PMs is reported to be 
between 1 and 7% in Caucasians and Africans.4,24,25 
In Europe, a north-south gradient, with a decreased 
prevalence of PMs in Southern Europe, has been 
observed.21 No patients in this cohort were 
genotyped as homozygous for the CYP2C19 *2 
allele and the frequency of the *2/*2 genotype was 
comparable to only six of the fourteen populations 
bordering the Mediterranean Sea included in the 
comparison.  
Twenty-five percent of this Maltese patient 
cohort was genotyped as heterozygous for the 
CYP2C19 *2 allele and phenotyped as IMs, while 
23% of the patients were phenotyped as UMs. 
These findings have relevant clinical implications 
vis-à-vis clopidogrel since these patients are at an 
increased risk of unwanted outcomes due to 
compromised clopidogrel activity. 
The CYP2C19 *2 allele is clinically important 
with respect to clopidogrel and has been associated 
with reduced formation of active metabolites and 
higher on-clopidogrel platelet reactivity (PR), 
leading to increased risk of adverse cardiovascular 
events in IMs and PMs compared to EMs.26-29  The 
strongest association is reported in patients with 
acute coronary syndrome undergoing PCI with stent 
placement, where carriers of the *2 allele are at 
higher risk of stent thrombosis compared to non-
carriers.27,30,31 According to the CPIC guidelines, an 
alternative P2Y12-receptor inhibitor, such as 
ticagrelor or prasugrel, should be considered in 
carriers of the *2 allele (25% in this patient cohort) 
provided there is no contra-indication.5    
There are mixed results on the clinical 
relevance of the CYP2C19 *17 allele with respect to 
clopidogrel (23% in this patient cohort), where 
some studies reported lower on-clopidogrel PR, 
enhanced response to clopidogrel and increased risk 
of bleeding, while other studies reported no effect 
of this allele on clinical outcomes.32-35 The CPIC 
guidelines recommend standard dosage of 
clopidogrel in UMs.5   
The UM phenotype is clinically relevant for 
other drugs where CYP2C19 genetic 
polymorphisms are implicated in variability of 
interpatient response, such as for proton pump 
inhibitors (PPIs), tricyclic antidepressants (TCAs), 
selective serotonin reuptake inhibitors (SSRIs) and 
voriconazole. Further study is recommended to 
assess the prevalence and clinical implications of 
CYP2C19 genetic polymorphisms in patients taking 
these drugs. 
For PPIs, UMs have shown less effective 
gastric acid suppression and decreased Helicobacter 
pylori eradication rates, hence an increase in dose is 
recommended.36 For TCAs (amitriptyline, 
clomipramine, doxepin, imipramine, trimipramine) 
and SSRIs (citalopram, escitalopram, sertraline), the 
UM phenotype is associated with increased 
metabolism and risk of sub-optimal response, hence 
the CPIC guidelines suggest an alternative drug not 
metabolised by CYP2C19.37,38 With respect to 
voriconazole, UMs are less likely to attain 
therapeutic concentrations with standard dosing and 
selection of an alternative agent not dependent on 
CYP2C19 metabolism as primary therapy is 
recommended.39 
 
Conclusion  
This study reports the frequency of CYP2C19 
*2 and *17 variant alleles in a cohort of Maltese 
patients on clopidogrel therapy. The high 
percentage of patients phenotyped as IMs (25%) 
indicates that CYP2C19 pharmacogenetic testing 
could be used to guide clinicians in the 
individualisation of antiplatelet therapy. This study 
serves as an example of pharmacogenetic testing to 
achieve precision medicine. 
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